丁二磺酸腺苷蛋氨酸联合复方甘草酸苷治疗酒精性肝硬化患者疗效及其对血清BGP水平的影响*

doi:10.3969/j.issn.1672-5069.2019.06.024

摘要/Abstract

摘要： 目的探讨应用丁二磺酸腺苷蛋氨酸肠溶片联合复方甘草酸苷治疗酒精性肝硬化患者的疗效及其对血清骨钙素（BGP）水平的影响。方法 2016年3月~2018年2月我院诊治的酒精性肝硬化患者276例,采用随机数字表法分为观察组（n=138）和对照组（n=138）。给予对照组患者丁二磺酸腺苷蛋氨酸肠溶片口服,观察组患者在对照组治疗的基础上给予复方甘草酸苷注射液静脉滴注,治疗3 w。采用放射免疫法检测血清BGP水平,采用ELISA法检测血清胰岛素样生长因子1（IGF-1）水平,采用化学发光免疫法检测血清透明质酸（HA）、黏连蛋白（LN）、IV型胶原（IV-C）和III型前胶原（PC-III）水平。结果在治疗结束时,观察组血清ALB为（36.8±10.3） g/L,显著高于对照组[（29.4±9.2） g/L,P<0.05],血清TBIL为（26.4±5.1） μmol/L,显著低于对照组[（47.3±9.4） μmol/L,P<0.05],血清GGT水平为（158.6±72.8） U/L,显著低于对照组[（254.6±100.4） U/L,P<0.05];观察组血清HA为（72.6±18.4） μg/L,显著低于对照组[（158.4±30.5） μg/L,P<0.05],LN为（87.4±8.3） μg/L,显著低于对照组[（165.3±19.8） μg/L,P<0.05],PC-III为（94.5±31.3） μg/L,显著低于对照组[（147.4±42.5） μg/L,P<0.05],IV-C为（64.3±9.5） μg/L,显著低于对照组[（98.4±26.4） μg/L,P<0.05];观察组血清IGF-1水平为（198.2±34.6）ng/ml,显著高于对照组[（162.5±30.5） ng/ml,P<0.05],BGP为（8.8±3.9） ng/ml,显著高于对照组[（6.7±3.0） ng/ml,P<0.05]。结论应用丁二磺酸腺苷蛋氨酸肠溶片联合复方甘草酸苷治疗酒精性肝硬化患者近期疗效显著,可显著改善患者肝功能指标,可能与升高了血清IGF-1和BGP水平有关。

关键词: 酒精性肝硬化, 丁二磺酸腺苷蛋氨酸, 复方甘草酸苷, 疗效, 骨钙素

Abstract: Objective The purpose of this study to investigate the efficacy of adenosine methionine and glycyrrhizin combination in the treatment of patients with alcoholic cirrhosis and its effect on serum osteocalcin （BGP） levels. Methods A total of 276 patients with alcoholic cirrhosis were recruited in our hospital between March 2016 and February 2018,and were randomly divided into observation group （n=138） and control group （n=138）. The patients in the control group were given adenosine methionine enteric-coated tablets,and the patients in the observation were given an intravenous infusion of compound glycyrrhizin at the base of adenosine methionine administration for three weeks. Serum BGP levels were assayed by radioimmunoassay and serum IGF-1 levels were detected by enzyme-linked immunosorbent assay. Serum f hyaluronic acid （HA）,laminin （LN）,type IV collagen（IV-C） and type III procollagen（PCIII） were detected by chemiluminescence immunoassay. Results Serum albumin level in the observation group was（36.8±10.3） g/L,significantly higher than[（29.4±9.2） g/L,P<0.05] in the control group,serum bilirumin level was（26.4±5.1） μmol/L,significantly lower than [（47.3±9.4） μmol/L,P<0.05] in the control group,and serum GGT level was （158.6±72.8） U/L,significantly lower than[（254.6±100.4） U/L,P<0.05] in the control group;serum HA level in the observation group was （72.6±18.4） μg/L, significantly lower than [（158.4±30.5） μg/L,P<0.05] in the control,serum LN level was（87.4±8.3） μg/L, significantly lower than [（165.3±19.8）μg/L,P<0.05] in the control,serum PCIII level was（94.5±31.3） μg/L,significantly lower than[（147.4±42.5） μg/L,P<0.05] in the control,and serum IV-C level was（64.3±9.5） μg/L,significantly lower than[（98.4±26.4） μg/L,P<0.05] in the control;serum IGF-1 level in the observation group was（198.2±34.6） ng/ml,significantly higher than [（162.5±30.5） ng/ml,P<0.05] in the control,and serum BGP level was （8.8±3.9） ng/ml,significantly higher than [（6.7±3.0） ng/ml,P<0.05] in the control group. Conclusion Application of adenosine methionine and glycyrrhizin is efficacious in the treatment of patients with alcoholic cirrhosis,which can effectively improve liver function tests,and significantly increase serum IGF-1 and BGP levels.

Key words: Alcoholic cirrhosis, Adenosine methionine, Glycyrrhizin, efficacy, Osteocalcin

朱娅鸽, 刘锦峰. 丁二磺酸腺苷蛋氨酸联合复方甘草酸苷治疗酒精性肝硬化患者疗效及其对血清BGP水平的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 872-875.

Zhu Yage, Liu Jinfeng.. Therapeutic efficacy of adenosine methionine and glycyrrhizin combination in treatment of patients with alcoholic cirrhosis and its effect on serum BGP levels[J]. Journal of Practical Hepatology, 2019, 22(6): 872-875.

参考文献

[1] Albano E,Stickel F.Targeting toll-like receptor 7/8 improves host anti-infective response in alcoholic cirrhosis. Gut,2018,67(10):1749-1750.
[2] Otete H,Deleuran T,Fleming KM,et al.Hip fracture risk in patients with alcoholic cirrhosis:a population-based study using English and Danish data. J Hepatol,2018,69(3):697-704.
[3] Ashwani K,Singal MS,Bhupinderjit S,et al.Recent trends in the epidemiology of alcoholic liver disease. Clin Liver Dis,2013,2(2):53-56.
[4] 张素梅,刘媗婷,李子文,等. 复方甘草酸苷联合苦参素治疗慢性肝炎患者对血清肝纤维化指标的影响. 实用肝脏病杂志,2014,17(3):309-310.
[5] 胡翠兰,刘纯钢,袁艳梅. 复方鳖甲软肝片联合复方甘草酸苷治疗代偿期肝硬化患者疗效观察. 实用肝脏病杂志,2014,17(2): 192-193.
[6] Victoria G,Anita L,Vgren S,et al.The reversed feto-maternal bile acid gradient in intrahepatic cholestasis of pregnancy is corrected by ursodeoxycholic acid. PLoS One,2014,9(1):e83828.
[7] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会. 酒精性肝病防治指南(2018年更新版).实用肝脏病杂志,2018,21(2):170-176.
[8] Noiret L,Baigent S,Jalan R.Arterial ammonia levels in cirrhosis are determined by systemic and hepatic hemodynamies,and by organ funetion:a quantitative modelling study. Liver Int,2014,34(6):e45-e55.
[9] Zhou JY,Jiang ZA,Zhao CY,et al.Long-term binge and escalating ethanol exposure causes necroinflammation and fibrosis in rat liver. Alcohol Clin Exp Res,2013,37(2):213-222.
[10] Wang ZG,Dou XB,Zhou ZX,et al.Adipose tissue-liver axis in alcoholic liver disease. World J Gastrointest Pathophysiol,2016,7(1):17-26.
[11] Matsui T,Yokoyama A,Matsushita S,et al.Effect of a comprehensive lifestyle modification program on the bone density of male heavy drinkers. Alcohol Clin Exp Res,2010,34(5):869-875.
[12] Steiner JL,Lang CH.Alcohol impairs skeletal muscle protein synthesis and mTOR signaling in a time-dependent manner following electrically stimulated muscle contraction. J Appl Physiol,2014,117(10):1170-1179.
[13] 胡翠兰,刘纯钢,袁艳梅. 复方鳖甲软肝片联合复方甘草酸苷治疗代偿期肝硬化患者疗效观察. 实用肝脏病杂志,2014,17(2):192-193.
[14] Leung J,Bonis PA,Kaplan MM.Colchicine or methotrexate,with ursodiol,are effective after 20 years in a subset of patients with primary biliary cirrhosis. Clin Gastroenterol Hepatol,2011,9(9):776-780.
[15] Dieffenbach P,DuBrock HM,Mouded M. Diagnosis and management of pulmonary hypertension in apatient with hereditary hemorrhagic telangiectasia,alcoholic cirrhosis,and congestive heart failure. Am J Respir Crit Care Med,2014,189:A4868.
[16] Weng CF,Chan DC,Chen YF,et al.Chronic hepatitis B infection presenting with chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS):a case report. J Med Case Rep,2015,9:266.
[17] Shimizu A,Kobayashi A,Yokoyama T,et al.Correlation between the serum levels of type IV collagen 7s domain and the risk of intractable ascites following liver resection for hepatocellular carcinoma:a propensity score-matched analysis. Surgery,2016,160(5):1244-1255.
[18] Chen YN,Hsu SL,Liao MY,et al.Ameliorative effect of curcumin encapsulated hyaluronic acid-PLA nanoparticles on thioacetamide-induced murine hepatic fibrosis. Int J Environ Res Public Health,2016,14(1):78-82.
[19] Tonon M1,Piano S1,Romano A,et al. Assessment of bone mineral density in patients with cirrhosis treated with third-generation nucleos(t)ide analogues:comparison between tenofovir and entecavir. Eur J Gastroenterol Hepatol,2018,30(3):284-290.
[20] Yakar S,Courtland H,Clemmons D.IGF-1 and bone:new discoveries from mouse models. J Bone Miner Res,2010,25(12):2543-2552.

丁二磺酸腺苷蛋氨酸联合复方甘草酸苷治疗酒精性肝硬化患者疗效及其对血清BGP水平的影响^*

Therapeutic efficacy of adenosine methionine and glycyrrhizin combination in treatment of patients with alcoholic cirrhosis and its effect on serum BGP levels

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	巴正武, 栗海龙, 杨慧. 能谱CT成像定量评估Budd-Chiari综合征患者TIPS术治疗前后肝功能状态临床价值研究*[J]. 实用肝脏病杂志, 2019, 22(5): 680-683.
[2]	张志成, 袁广庆, 莫灿均. 肝动脉栓塞术治疗三种类型肝血管瘤患者疗效及安全性分析*[J]. 实用肝脏病杂志, 2019, 22(5): 736-739.
[3]	白一春, 邓霁红, 梅小平. 影响聚乙二醇干扰素α-2b治疗慢性乙型肝炎患者疗效的多因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 490-493.
[4]	严玲玲, 胡东辉, 黄艳芳. 腺苷蛋氨酸联合多烯磷酯酰胆碱治疗妊娠期肝内胆汁淤积症患者临床疗效初步研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 530-533.
[5]	王宝丹, 李萌, 高于. α-干扰素治疗慢性乙型肝炎儿童疗效及其影响疗效的因素分析[J]. 实用肝脏病杂志, 2019, 22(3): 345-348.
[6]	袁春晖, 李春雨, 李红丽, 赵红娜, 王文红, 孟庆旭, 张中学. 国产聚乙二醇化干扰素α治疗HBeAg阳性慢性乙型肝炎患者疗效研究[J]. 实用肝脏病杂志, 2019, 22(3): 353-356.
[7]	徐曼曼, 陈煜, 李爽. 特利加压素联合白蛋白输注治疗肝肾综合征患者疗效及尿NGAL和KIM-1对疗效的预测价值[J]. 实用肝脏病杂志, 2019, 22(3): 385-388.
[8]	王秀清,马艳君,詹晋莉. 肝动脉化疗栓塞术联合超声引导下微波消融术治疗特殊部位原发性肝癌患者疗效及安全性分析 ^*[J]. 实用肝脏病杂志, 2019, 22(2): 260-263.
[9]	赵鹏, 王磊. 聚乙二醇化干扰素-α对不同基因型慢性丙型肝炎患者治疗效果比较^*[J]. 实用肝脏病杂志, 2019, 22(1): 57-60.
[10]	闫焕杰, 张淑芹, 赵文静. 自体骨髓干细胞移植治疗慢加急性乙型肝炎肝衰竭患者疗效初步研究[J]. 实用肝脏病杂志, 2019, 22(1): 81-84.
[11]	曹艳平, 隋洪婷, 潘猛, 曲宝聚, 朴红心. 恩替卡韦联合聚乙二醇干扰素或胸腺素治疗代偿期乙型肝炎肝硬化2年疗效随访^*[J]. 实用肝脏病杂志, 2019, 22(1): 93-96.
[12]	王禅, 秦伟, 戴勇, 李晓峰, 张成强. 自体外周血干细胞移植治疗乙型肝炎肝硬化患者临床疗效及其对外周血T淋巴细胞亚群的影响[J]. 实用肝脏病杂志, 2019, 22(1): 97-100.
[13]	马履翔, 张雪松. 超声引导下经皮射频消融治疗小肝癌患者疗效及预后分析^*[J]. 实用肝脏病杂志, 2019, 22(1): 125-128.
[14]	黄娇凤, 林苏, 王明芳, 黄映芳, 熊美连, 朱月永. 恩替卡韦治疗慢性乙型肝炎合并非酒精性脂肪性肝病患者疗效及其对肝组织脂肪变的影响^*[J]. 实用肝脏病杂志, 2018, 21(6): 863-867.
[15]	安红杰, 周东方. 恩替卡韦联合复方鳖甲软肝片治疗乙型肝炎肝硬化患者疗效及转归研究^*[J]. 实用肝脏病杂志, 2018, 21(6): 903-906.